Connect Biopharma to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Connect Biopharma (Nasdaq: CNTB), a clinical-stage biopharmaceutical company specializing in Asthma and COPD treatments, has announced its participation in two major investor conferences in March 2025.

The company will present at the Leerink Partners Global Biopharma Conference on March 12, 2025, at 1:40 p.m. ET, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 2:30 p.m. ET. Both presentations will be in a fireside chat format.

Live webcasts will be available on Connect's investor relations website, with archived replays accessible for approximately 90 days after the events.

News Market Reaction

-4.09%

1 alert

-4.09% News Effect

On the day this news was published, CNTB declined 4.09%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in Asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced that company management will participate in the following upcoming conferences:

Leerink Partners Global Biopharma Conference
Format: Fireside Chat
Date: Wednesday, March 12, 2025
Time: 1:40 p.m. ET
Webcast Link: Register Here

H.C. Wainwright 3^rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Format: Fireside Chat
Date: Thursday, March 27, 2025
Time: 2:30 p.m. ET
Webcast Link: Register Here

Live webcasts for the events will also be accessible on Connect’s website in the Investors section under Presentations, Events & News at  investors.connectbiopharm.com. An archived replay of the webcasts will be available for approximately 90 days following the event.

About Connect Biopharma
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on advancing Rademikibart™, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform care in Asthma and COPD. Rademikibart has the potential to drive significant chronic utilization in Asthma and COPD with an initial focus on acute indications, which represent an untapped opportunity targeting the ~1 million asthma and ~1.3 million COPD patients in the U.S. alone who experience acute exacerbations annually. Rademikibart has demonstrated encouraging efficacy and safety in Phase 2 studies, as well as rapid onset of action as early as 24 hours. Learn more at www.connectbiopharm.com.

Investor Relations & Media Contact:
David Szekeres
President
Connect Biopharma
dszekeres@connectpharm.com

FAQ

When is Connect Biopharma (CNTB) presenting at the Leerink Partners Conference in March 2025?

Connect Biopharma will present at the Leerink Partners Global Biopharma Conference on March 12, 2025, at 1:40 p.m. ET.

What type of presentation format will CNTB use at the March 2025 investor conferences?

Both presentations will be in a fireside chat format.

How long will CNTB's conference webcasts be available for replay?

The webcasts will be available for replay for approximately 90 days following each event.

What therapeutic areas does Connect Biopharma (CNTB) focus on?

Connect Biopharma focuses on transforming acute and chronic care in Asthma and Chronic Obstructive Pulmonary Disease (COPD).

When is CNTB presenting at the H.C. Wainwright Conference in March 2025?

Connect Biopharma will present at the H.C. Wainwright Conference on March 27, 2025, at 2:30 p.m. ET.